A Phase III Prospective Active and Placebo-Controlled Randomized Trial of Vilazodone in the Treatment of Major Depressive Disorder.
Shubhadeep Sinha, Sreenivasa Chary, Pankaj Thakur...
https://pubmed.ncbi.nlm.nih.gov/34513348/Actively Recruiting
Led by Sichuan Credit Pharmaceutical Co., Ltd. · Updated on 2026-11-03
60
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are studying the long-term effects of CreNeuroS CNS Fish Oil Plus Softgels in people with Major Depressive Disorder MDD who achieved remission after an 8-week treatment in a previous study. This extension trial evaluates how well remission is maintained, relapse is prevented, and the safety of CreNeuroS over a 52-week period. The study is randomized and open-label with multiple centers involved. After completing the initial 8-week treatment phase, eligible participants who remain stable will enter a transition or taper period lasting about 2 to 4 weeks without intervention. Following this, participants are randomly assigned to one of three groups no CreNeuroS supplementation, daily intake of one CreNeuroS capsule, or daily intake of two capsules. They will be monitored for one year to assess ongoing remission, relapse rates, clinical outcomes, and safety. During the study, participants will attend scheduled visits at weeks 0, 12, 26, 40, and 52 to evaluate their symptoms using the HAM-D-17 scale and to monitor for any adverse events or health changes. Researchers will track relapse-free status and gather information on side effects and overall safety. The total duration of participation in this extension phase is approximately 52 weeks following the baseline visit.
CONDITIONS
A Randomized, 52-Week Extension Study to Evaluate the Maintenance of Remission, Relapse Prevention, and Long-Term Safety of CreNeuroS™ in Patients With Major Depressive Disorder Who Achieved Remission Following an 8-Week Parent Study
H
Hitesh Shah
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Sichuan Credit Pharmaceutical Co., Ltd.
Lead Sponsor
Vivotech Research Lab Pvt Ltd
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit
Duration - Approximately 2 to 4 weeks
Participants undergo a 2 to 4 week period tapering off prior antidepressant treatment with no study intervention.
Visits as needed to monitor clinical stability
Duration - 52 weeks
Participants are randomized to one of three groups: no CreNeuroS™ supplementation, one capsule daily, or two capsules daily, and followed to assess remission maintenance, relapse prevention, and safety.
Visits at weeks 0, 12, 26, 40, and 52
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Shubhadeep Sinha, Sreenivasa Chary, Pankaj Thakur...
https://pubmed.ncbi.nlm.nih.gov/34513348/Sichuan Credit Pharmaceutical Co., Ltd.
Lead Sponsor
Vivotech Research Lab Pvt Ltd
Collaborating Sponsor